Staybla

Staybla Uses, Dosage, Side Effects, Food Interaction and all others data.

Staybla is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.

Staybla is an antimuscarinic agent which acts to reduce the frequency of urination in patients with overactive bladder .

Trade Name Staybla
Generic Imidafenacin
Imidafenacin Other Names Imidafenacin
Type
Formula C20H21N3O
Weight Average: 319.408
Monoisotopic: 319.168462308
Protein binding

Imidafenacin is 88% bounf by human plasma proteins . It binds to serum albumin and α1-acid glycoprotein.

Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Staybla
Staybla

Uses

Staybla is an antispasmodic with anticholinergic effects used to reduce urinary frequency.

Used in the treatment of overactive bladder .

Staybla is also used to associated treatment for these conditions: Urinary Bladder, Overactive, Urinary Incontinence (UI), Urinary Urge Incontinence, Urinary Urgency, Increased frequency of urination

How Staybla works

Staybla binds to and antagonizes muscarinic M1 and M3 receptors with high affinity . It also antagonizes muscarinic M2 receptors but with lower affinity. M3 receptors stimulate contraction of the detrusor muscle in the bladder via release of calcium from the sarcoplasmic reticulum . M2 receptors are also present in the detrusor muscle but serve to inhibit adenylate cyclase which reduces the relaxation mediated by β adrenergic receptors. Finally, M1 receptors are present on the parasympathetic neurons which release acetylcholine in the bladder. They act as an autocrine positive feedback loop and further increase release of acetylcholine. Antagonism of these receptors by imidafenacin prevents contraction of the bladder's detrusor muscle, prevents inhibition of the relation produced by sympathetic tone, and reduces acetylcholine release. Together these reduce the frequency of urination.

Toxicity

Clinically significant adverse reactions to imidafenacin are acute glaucoma (0.06%), urinary retention (0.03%), and heptic dysfunction (0.02%) . The most common adverse effects observed with imidafenacin are thirst (37.7%), constipation (13.6%).

Volume of Distribution

The estimated volume of distribution is 43.9 L .

Elimination Route

The absolute oral bioavailability is 57.8% . Tmax is 1-3 h after administration.

Half Life

The half life of elimination is 3 h .

Clearance

The estimated clearance is 21.2 L/h .

Elimination Route

10% is excreted in the urine as the parent compound . Most is eliminated by metabolism thought to be mediated by CYP3A4 and UGT1A4.

Innovators Monograph

You find simplified version here Staybla

*** Taking medicines without doctor's advice can cause long-term problems.
Share